<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00975507</url>
  </required_header>
  <id_info>
    <org_study_id>V221-009</org_study_id>
    <secondary_id>2009_660</secondary_id>
    <nct_id>NCT00975507</nct_id>
  </id_info>
  <brief_title>ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)</brief_title>
  <official_title>A Pilot Study to Compare the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine and the Concomitant Administration of the Currently Licensed VARIVAX™ and M-M-R II™ in Healthy Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare Measles, Mumps, Rubella, and Varicella Vaccine (V221) and concomitant
      administration of Varivax and M-M-R II vaccines in healthy children.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 1998</start_date>
  <completion_date type="Actual">June 1999</completion_date>
  <primary_completion_date type="Actual">January 1999</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Postvaccination Varicella Antibody Titer ≥5 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Units/mL for Subjects Initially Seronegative (a Titer of &lt;0.6 gpELISA Units/mL) to Varicella at Baseline</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Antibody Response to Varicella at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer of &lt;0.6 gpELISA units/mL) to Varicella at Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Postvaccination Measles ELISA Antibody Titer ≥207.8 mIU/mL</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Antibody Response to Measles at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt;207.8 mIU/mL) to Measles at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Postvaccination Varicella Antibody Titer ≥5 gpELISA Units/mL for Subjects Initially With Varicella Antibody Titer &lt;1.25 gpELISA Units/mL at Baseline</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Antibody Response to Varicella at 6 Weeks Postvaccination for Subjects Initially With Varicella Antibody Titer &lt;1.25 gpELISA units/mL at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Postvaccination Mumps ELISA Antibody Titer ≥2.0 Ab Units/mL</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Antibody Response to Mumps at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt;2.0 Ab Units/mL) to Mumps at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Postvaccination Rubella ELISA Antibody Titer ≥10 IU/mL</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Antibody Response to Rubella at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt;10 IU/mL) to Rubella at Baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">480</enrollment>
  <condition>Measles</condition>
  <condition>Mumps</condition>
  <condition>Rubella</condition>
  <condition>Varicella</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ProQuad™ (V221) + Placebo Followed by ProQuad™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>M-M-R™ II + VARIVAX™</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live</intervention_name>
    <description>a single 0.5 mL subcutaneous injection of V221 at Day 0 and Day 90</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ProQuad™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>a single 0.5 mL subcutaneous placebo injection at Day 0</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Varivax</intervention_name>
    <description>a single 0.5 mL subcutaneous injection of Varivax at Day 0</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: M-M-R II</intervention_name>
    <description>a single 0.5 mL subcutaneous injection of M-M-R II at Day 0</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good health

          -  Negative clinical history of varicella, shingles, measles, mumps, and rubella

        Exclusion Criteria:

          -  Previous receipt of measles, mumps, rubella and/or varicella vaccine either alone or
             in combination

          -  Any immune impairment or deficiency

          -  Exposure to measles, mumps, rubella, varicella, or zoster in the 4 weeks prior to
             vaccination

          -  Vaccination with an inactive vaccine with in the past 14 days

          -  Vaccination with a live vaccine within the past 30 days

          -  Immune globulin or any blood product administered in the past 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <reference>
    <citation>Shinefield H, Black S, Digilio L, Reisinger K, Blatter M, Gress JO, Brown ML, Eves KA, Klopfer SO, Schödel F, Kuter BJ. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005 Aug;24(8):665-9.</citation>
    <PMID>16094217</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2009</study_first_submitted>
  <study_first_submitted_qc>September 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2009</study_first_posted>
  <results_first_submitted>September 23, 2009</results_first_submitted>
  <results_first_submitted_qc>January 25, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 10, 2010</results_first_posted>
  <last_update_submitted>October 5, 2015</last_update_submitted>
  <last_update_submitted_qc>October 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Measles</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Rubella</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>2 clinical sites in the United States
Date of first participant visit: 24-Mar-1998
Date of last participant visit: 05-Jan-1999</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ProQuad™ + Placebo Followed by ProQuad™</title>
          <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) containing a high varicella component (~40,000 PFU/0.5 mL-dose) with a standard measles component (~3.7 log10 TCID50/0.5 mL dose) + placebo administered concomitantly at separate injection sites on Day 0. Second dose of ProQuad™ containing a high varicella component (~40,000 PFU/0.5 mL-dose) with a standard measles component (~3.7 log10 TCID50/0.5 mL dose) administered approximately 90 days (Day 90) after the first dose.</description>
        </group>
        <group group_id="P2">
          <title>M-M-R™ II + VARIVAX™</title>
          <description>VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="323"/>
                <participants group_id="P2" count="157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated at Visit 1</title>
              <participants_list>
                <participants group_id="P1" count="323"/>
                <participants group_id="P2" count="157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated at Visit 2</title>
              <participants_list>
                <participants group_id="P1" count="310"/>
                <participants group_id="P2" count="0">Per-protocol, subjects receiving M-M-R™ II + VARIVAX™ at Visit 1 were not vaccinated at Visit 2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ProQuad™ + Placebo Followed by ProQuad™</title>
          <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) containing a high varicella component (~40,000 PFU/0.5 mL-dose) with a standard measles component (~3.7 log10 TCID50/0.5 mL dose) + placebo administered concomitantly at separate injection sites on Day 0. Second dose of ProQuad™ containing a high varicella component (~40,000 PFU/0.5 mL-dose) with a standard measles component (~3.7 log10 TCID50/0.5 mL dose) administered approximately 90 days (Day 90) after the first dose.</description>
        </group>
        <group group_id="B2">
          <title>M-M-R™ II + VARIVAX™</title>
          <description>VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="323"/>
            <count group_id="B2" value="157"/>
            <count group_id="B3" value="480"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.1" spread="1.9"/>
                    <measurement group_id="B2" value="14.0" spread="1.7"/>
                    <measurement group_id="B3" value="14.1" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Pacific</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Postvaccination Varicella Antibody Titer ≥5 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Units/mL for Subjects Initially Seronegative (a Titer of &lt;0.6 gpELISA Units/mL) to Varicella at Baseline</title>
        <description>Antibody Response to Varicella at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer of &lt;0.6 gpELISA units/mL) to Varicella at Baseline</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to varicella at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™+Placebo Followed by ProQuad™ - (1 Injection ProQuad™)</title>
          </group>
          <group group_id="O2">
            <title>ProQuad™+Placebo Followed by ProQuad™ - (2 Injection ProQuad™)</title>
          </group>
          <group group_id="O3">
            <title>M-M-R™ II + VARIVAX™ (1 Injection)</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Varicella Antibody Titer ≥5 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Units/mL for Subjects Initially Seronegative (a Titer of &lt;0.6 gpELISA Units/mL) to Varicella at Baseline</title>
          <description>Antibody Response to Varicella at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer of &lt;0.6 gpELISA units/mL) to Varicella at Baseline</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to varicella at baseline, and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228"/>
                    <measurement group_id="O2" value="237"/>
                    <measurement group_id="O3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Postvaccination Measles ELISA Antibody Titer ≥207.8 mIU/mL</title>
        <description>Antibody Response to Measles at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt;207.8 mIU/mL) to Measles at Baseline</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to measles at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™+Placebo Followed by ProQuad™ - (1 Injection ProQuad™)</title>
          </group>
          <group group_id="O2">
            <title>ProQuad™+Placebo Followed by ProQuad™ - (2 Injection ProQuad™)</title>
          </group>
          <group group_id="O3">
            <title>M-M-R™ II + VARIVAX™ (1 Injection)</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Measles ELISA Antibody Titer ≥207.8 mIU/mL</title>
          <description>Antibody Response to Measles at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt;207.8 mIU/mL) to Measles at Baseline</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to measles at baseline, and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="288"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290"/>
                    <measurement group_id="O2" value="284"/>
                    <measurement group_id="O3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Postvaccination Varicella Antibody Titer ≥5 gpELISA Units/mL for Subjects Initially With Varicella Antibody Titer &lt;1.25 gpELISA Units/mL at Baseline</title>
        <description>Antibody Response to Varicella at 6 Weeks Postvaccination for Subjects Initially With Varicella Antibody Titer &lt;1.25 gpELISA units/mL at Baseline</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, Varicella Antibody Titer &lt;1.25 gpELISA units/mL at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™+Placebo Followed by ProQuad™ - (1 Injection ProQuad™)</title>
          </group>
          <group group_id="O2">
            <title>ProQuad™+Placebo Followed by ProQuad™ - (2 Injection ProQuad™)</title>
          </group>
          <group group_id="O3">
            <title>M-M-R™ II + VARIVAX™ (1 Injection)</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Varicella Antibody Titer ≥5 gpELISA Units/mL for Subjects Initially With Varicella Antibody Titer &lt;1.25 gpELISA Units/mL at Baseline</title>
          <description>Antibody Response to Varicella at 6 Weeks Postvaccination for Subjects Initially With Varicella Antibody Titer &lt;1.25 gpELISA units/mL at Baseline</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, Varicella Antibody Titer &lt;1.25 gpELISA units/mL at baseline, and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="278"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264"/>
                    <measurement group_id="O2" value="275"/>
                    <measurement group_id="O3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Postvaccination Mumps ELISA Antibody Titer ≥2.0 Ab Units/mL</title>
        <description>Antibody Response to Mumps at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt;2.0 Ab Units/mL) to Mumps at Baseline</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to mumps at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™+Placebo Followed by ProQuad™ - (1 Injection ProQuad™)</title>
          </group>
          <group group_id="O2">
            <title>ProQuad™+Placebo Followed by ProQuad™ - (2 Injection ProQuad™)</title>
          </group>
          <group group_id="O3">
            <title>M-M-R™ II + VARIVAX™ (1 Injection)</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Mumps ELISA Antibody Titer ≥2.0 Ab Units/mL</title>
          <description>Antibody Response to Mumps at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt;2.0 Ab Units/mL) to Mumps at Baseline</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to mumps at baseline, and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="283"/>
                <count group_id="O3" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292"/>
                    <measurement group_id="O2" value="283"/>
                    <measurement group_id="O3" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Postvaccination Rubella ELISA Antibody Titer ≥10 IU/mL</title>
        <description>Antibody Response to Rubella at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt;10 IU/mL) to Rubella at Baseline</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to rubella at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™+Placebo Followed by ProQuad™ - (1 Injection ProQuad™)</title>
          </group>
          <group group_id="O2">
            <title>ProQuad™+Placebo Followed by ProQuad™ - (2 Injection ProQuad™)</title>
          </group>
          <group group_id="O3">
            <title>M-M-R™ II + VARIVAX™ (1 Injection)</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Rubella ELISA Antibody Titer ≥10 IU/mL</title>
          <description>Antibody Response to Rubella at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt;10 IU/mL) to Rubella at Baseline</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to rubella at baseline, and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="290"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="289"/>
                    <measurement group_id="O2" value="275"/>
                    <measurement group_id="O3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The number of participants listed as &quot;at risk&quot; is the number of participants with follow-up.</desc>
      <group_list>
        <group group_id="E1">
          <title>ProQuad™ + Placebo Then ProQuad™ - ProQuad™ (1 Injection)</title>
          <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) containing a high varicella component (~40,000 PFU/0.5 mL-dose) with a standard measles component (~3.7 log10 TCID50/0.5 mL dose) + placebo administered concomitantly at separate injection sites on Day 0.</description>
        </group>
        <group group_id="E2">
          <title>ProQuad™ + Placebo Then ProQuad™ - ProQuad™ (2 Injections)</title>
          <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) containing a high varicella component (~40,000 PFU/0.5 mL-dose) with a standard measles component (~3.7 log10 TCID50/0.5 mL dose) + placebo administered concomitantly at separate injection sites on Day 0. Second dose of ProQuad™ containing a high varicella component (~40,000 PFU/0.5 mL-dose) with a standard measles component (~3.7 log10 TCID50/0.5 mL dose) administered approximately 90 days (Day 90) after the first dose.</description>
        </group>
        <group group_id="E3">
          <title>M-M-R™ II + VARIVAX™ (1 Injection)</title>
          <description>VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Merck CRISP</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, rotovirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Infection, viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>Merck CRISP</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="238" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="110" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Otitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, Viral</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Gastroenteritis, Infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Infection, Respiratory, Upper</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Venipuncture Site</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Bite/Sting, Non-Venomous</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Congestion, Nasal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Congestion, Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis, Contact</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Dermatomycosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Miliaria Rubra</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Rash, Measles/Rubella-Like</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Rash, Varicella-Like</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Viral Exanthema</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Erythema (ProQuad Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain/Tenderness/Soreness (ProQuad Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rash (ProQuad Injection-site)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Swelling (ProQuad Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Ecchymosis (Varivax Injection-site)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Erythema (Varivax Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pain/Tenderness/Soreness (Varivax Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Swelling (Varivax Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pain/Tenderness/Soreness (M-M-R II Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

